Publications Repository 2011

Boyd, KD (2011) Gender disparities in the tumor genetics and clinical outcome of multiple myeloma. Cancer Epidemiology, Biomarkers & Prevention 2011; 20: 8, 1703-1707
Gascón, Pete et al. (2011a) Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim. Critical Reviews in Oncology/Hematology 77 (2011) 184–197
Gascón, Pere et al (2011b) Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments. Critical Reviews in Oncology/Hematology 77 (2011) 198–200
Johnson DC et al. (2011) Genetic Factors Underlying the Risk of Thalidomide-Related Neuropathy in Patients With Multiple Myeloma Journal of Clinical Oncology 29:797-804.
Morgan GJ et al. (2011a) Cyclophosphamide, Thalidomide, and Dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation Blood. 2011; 118: 1231-1238
Morgan GJ et al.(2011b) Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncology 2011; 12(8): 743-752.
Tapper W et al. (2011) Heterogeneity in the prognostic significance of 12p deletion and chromosome 5 amplification in Multiple Myeloma. In: Journal of Clinical Oncology 2011; 29(2) e37-e39
Whittle, R & Taylor PC (2011) Circulating B-cell activating factor level predicts clinical response of chronic graft-versus-host disease to extracorporeal photopheresis. Blood. 2011 Dec 8;118(24):6446-9
Wu, P et al. (2011) A gene expression based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatment. Clinical Cancer Research 2011; 17: 6347-6355
Yokoyama S et al. (2011) A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011;480 (7375):99-103